Literature DB >> 18258440

Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects.

Ryoko Takasawa1, Saki Takahashi, Kazunori Saeki, Satoshi Sunaga, Atsushi Yoshimori, Sei-ichi Tanuma.   

Abstract

Glyoxalase I (GLO I) is the rate-limiting enzyme for detoxification of methylglyoxal (MG), a side product of glycolysis, which is able to induce apoptosis. Since GLO I is known to be highly expressed in the most tumor cells and little in normal cells, specific inhibitors of this enzyme have been expected as effective anticancer drugs. The purpose of this study is a good construction of the human GLO I/inhibitor pharmacophore to obtain unique human GLO I inhibitory seed compounds for the development of useful anticancer drugs. Here, we selected natural flavonoid compounds that possess a plane configuration of cis C-4 ketone and C-5 hydroxy groups as the substrate (MG) transition-state mimetic structure. These compounds were examined the inhibitory abilities to human GLO I activity and analyzed their structure-activity relationships to determine an important pharmacophore of flavonoids for the human GLO I binding. Our results point to the contribution of hydroxy groups at the B ring of flavonoids to the effective inhibition of the human GLO I. Based on the binding mode of flavonoids, we constructed the human GLO I/inhibitor pharmacophore. This work delivers the first three-dimensional (3D) structural data and explains certain flavonoids interact specifically with the human GLO I.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258440     DOI: 10.1016/j.bmc.2008.01.031

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  16 in total

1.  Structural basis for 18-β-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor.

Authors:  Hong Zhang; Qiang Huang; Jing Zhai; Yi-ning Zhao; Li-ping Zhang; Yun-yun Chen; Ren-wei Zhang; Qing Li; Xiao-peng Hu
Journal:  Acta Pharmacol Sin       Date:  2015-08-17       Impact factor: 6.150

2.  Phenolic constituents from stem bark of Erythrina poeppigiana and their inhibitory activity on human glyoxalase I.

Authors:  Kiyomi Hikita; Hitoshi Tanaka; Tomiyasu Murata; Kuniki Kato; Miyuki Hirata; Tatsuko Sakai; Norio Kaneda
Journal:  J Nat Med       Date:  2014-04-23       Impact factor: 2.343

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

4.  Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.

Authors:  Nizar A Al-Shar'i; Qosay A Al-Balas; Rand A Al-Waqfi; Mohammad A Hassan; Amer E Alkhalifa; Nehad M Ayoub
Journal:  J Comput Aided Mol Des       Date:  2019-10-19       Impact factor: 3.686

5.  Reduction of oxidative stress and ornithine decarboxylase expression in a human prostate cancer cell line PC-3 by a combined treatment with α-tocopherol and naringenin.

Authors:  Piera Torricelli; Antonia Concetta Elia; Gabriele Magara; Giordana Feriotto; Cinzia Forni; Ilaria Borromeo; Angelo De Martino; Claudio Tabolacci; Carlo Mischiati; Simone Beninati
Journal:  Amino Acids       Date:  2021-01-04       Impact factor: 3.520

6.  Genome-Wide Expression Analysis of Glyoxalase I Genes Under Hyperosmotic Stress and Existence of a Stress-Responsive Mitochondrial Glyoxalase I Activity in Durum Wheat (Triticum durum Desf.).

Authors:  Mario Soccio; Marianna Marangi; Maura N Laus
Journal:  Front Plant Sci       Date:  2022-06-27       Impact factor: 6.627

Review 7.  Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development.

Authors:  Katherine M J McMurray; Margaret G Distler; Preetpal S Sidhu; James M Cook; Leggy A Arnold; Abraham A Palmer; Leigh D Plant
Journal:  Biochem Soc Trans       Date:  2014-04       Impact factor: 5.407

8.  Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes.

Authors:  Pamela Maher; Richard Dargusch; Jennifer L Ehren; Shinichi Okada; Kumar Sharma; David Schubert
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

9.  Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity.

Authors:  Thore Santel; Gabi Pflug; Nasr Y A Hemdan; Angelika Schäfer; Marcus Hollenbach; Martin Buchold; Anja Hintersdorf; Inge Lindner; Andreas Otto; Marina Bigl; Ilka Oerlecke; Antje Hutschenreuther; Antje Hutschenreuter; Ulrich Sack; Klaus Huse; Marco Groth; Claudia Birkemeyer; Wolfgang Schellenberger; Rolf Gebhardt; Mathias Platzer; Thomas Weiss; Mookambeswaran A Vijayalakshmi; Monika Krüger; Gerd Birkenmeier
Journal:  PLoS One       Date:  2008-10-23       Impact factor: 3.240

10.  Novel glyoxalase-I inhibitors possessing a "zinc-binding feature" as potential anticancer agents.

Authors:  Qosay A Al-Balas; Mohammad A Hassan; Nizar A Al-Shar'i; Nizar M Mhaidat; Ammar M Almaaytah; Fatima M Al-Mahasneh; Israa H Isawi
Journal:  Drug Des Devel Ther       Date:  2016-08-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.